Literature DB >> 20603049

Heart involvement in Churg-Strauss syndrome: retrospective study in French Burgundy population in past 10 years.

J Vinit1, P Bielefeld, G Muller, P Pfitzenmeyer, P Bonniaud, B Lorcerie, J F Besancenot.   

Abstract

INTRODUCTION: Heart manifestations of Churg-Strauss syndrome (CSS) are varied. In the early stages of the disease, it is difficult to distinguish between lesions that are specific to CSS and those of other etiologies. The aim of our work was to compare the characteristics of patients with heart manifestations linked or not to Churg-Strauss syndrome.
MATERIAL AND METHODS: We recorded all clinical symptoms of patients with CSS hospitalized between 1998 and 2008 in Burgundy, France, and determined the possible relationships between heart symptoms and CSS.
RESULTS: From a cohort of 31 patients, we found 20 with heart lesions. When heart lesions were present, we noted fewer initial symptoms of digestive disorders (p<0.05), lower levels of lung infiltrates and fewer anti-MPO pANCA (p<0.05). Heart lesions were linked to CSS in 75% of cases. Their patients were thus younger than those in the other cardiac patients (p<0.05), were more likely to have clinical manifestations of heart involvement at diagnosis, were less likely to have lung infiltrates on the X-ray at diagnosis and during flare-ups and less likely to have lung abnormalities on X-rays during flare-ups (p<0.05) and higher level of leucocytes and eosinophils at diagnosis.
CONCLUSION: Heart lesions directly attributable to CSS are frequent, severe and probably underestimated. A specific physiopathology that is not mediated by ANCA seems to be involved in the genesis of CSS-related heart lesions.

Entities:  

Mesh:

Year:  2010        PMID: 20603049     DOI: 10.1016/j.ejim.2010.05.004

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  9 in total

1.  Sudden cardiac death caused by coronary vasculitis.

Authors:  Katsuya Norita; Sofia V de Noronha; Mary N Sheppard
Journal:  Virchows Arch       Date:  2012-02-04       Impact factor: 4.064

2.  Ventricular tachycardia as the first manifestation of Churg-Strauss syndrome.

Authors:  Margarita Budanova; Lubov Mitrofanova; Andrey Kozlenok; Darja Ryzhkova; Aleksey Maslyanskiy; Olga Moiseeva
Journal:  J Cardiol Cases       Date:  2016-11-22

Review 3.  Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.

Authors:  Durga Prasanna Misra; Sajjan N Shenoy
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

Review 4.  Cardiac MRI in Autoimmune Diseases: Where Are We Now?

Authors:  Natalia G Vallianou; Eleni Geladari; Fotis Panagopoulos; Maria Kalantzi
Journal:  Curr Cardiol Rev       Date:  2021

5.  Immunosuppressive therapy ameliorates refractory vasospastic angina, severe pulmonary hypertension, and bronchiolitis in a patient with eosinophilic granulomatosis with polyangiitis: a case report.

Authors:  Ryo Konno; Shunsuke Tatebe; Tsuyoshi Shirai; Hiroaki Shimokawa
Journal:  Eur Heart J Case Rep       Date:  2018-04-25

6.  A case report of myocarditis secondary to eosinophilic granulomatosis with polyangiitis.

Authors:  Dorina-Gabriela Condurache; Zahra Raisi-Estabragh; Rohit Baslas; Shahir Hamdulay
Journal:  Eur Heart J Case Rep       Date:  2022-07-25

Review 7.  CMR in inflammatory vasculitis.

Authors:  Subha V Raman; Ashish Aneja; Wael N Jarjour
Journal:  J Cardiovasc Magn Reson       Date:  2012-11-30       Impact factor: 5.364

8.  Myocarditis: diagnosis and treatment.

Authors:  Maya Guglin; Leelakrishna Nallamshetty
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12

9.  Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors.

Authors:  Suying Liu; Ling Guo; Zhaocui Zhang; Mengtao Li; Xiaofeng Zeng; Li Wang; Yongtai Liu; Fengchun Zhang
Journal:  Ther Adv Chronic Dis       Date:  2021-01-22       Impact factor: 5.091

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.